Selling Intel, Buying Qualcomm: Why This Billionaire Is Betting on an ‘Atypical’ AI Chip Stock Billionaire investor David Tepper is making moves again, and his latest target is not your typical AI chip company. According to the latest 13F filing from his hedge fund, Appaloosa Management, the investment maestro known for his contrarian bets and turnaround plays executed a notable portfolio shift in...
Selling Intel, Buying Qualcomm: Why This Billionaire Is Betting on an ‘Atypical’ AI Chip Stock Billionaire investor David Tepper is making moves again, and his latest target is not your typical AI chip company. According to the latest 13F filing from his hedge fund, Appaloosa Management, the investment maestro known for his contrarian bets and turnaround plays executed a notable portfolio shift in Q3 2025. He significantly trimmed his stakes in high-flying AI beneficiaries—including Intel (INTC), Oracle (ORCL), and a long-time holding Micron Technology (MU)—and turned his attention to Qualcomm (QCOM), a stock that hasn’t fully taken off with the AI trend. Taking Profits Off the Table Tepper’s maneuvers showcase his classic “buy low, sell high” discipline. Intel (INTC) : Tepper likely booked a substantial gain on Intel within just a few months. He bought in during Q2 after the stock had fallen considerably from its late 2023/early 2024 highs. When shares surged in August following news of the U.S. government taking a stake in the chipmaker, he wisely took profits. : Tepper likely booked a substantial gain on Intel within just a few months. He bought in during Q2 after the stock had fallen considerably from its late 2023/early 2024 highs. When shares surged in August following news of the U.S. government taking a stake in the chipmaker, he wisely took profits. Oracle (ORCL) : Having initiated a position in Oracle in late 2023, possibly eyeing its underappreciated AI infrastructure potential, Tepper sold a large portion of his stake in early 2025 after steady gains through 2024. The subsequent rocket ride in Q2 and Q3 last year, fueled by a massive $300 billion contract with OpenAI that pushed Oracle toward a $1 trillion valuation, likely prompted him to exit the position entirely. : Having initiated a position in Oracle in late 2023, possibly eyeing its underappreciated AI infrastructure potential, Tepper sold a large portion of his stake in early 2025 after steady ga...
(RTTNews) - Merck & Co Inc. (MRK) is no longer in discussions to acquire biotech company Revolution Medicines, according to a report from the Wall Street Journal citing people familiar with the matter. The pharmaceutical giant had recently been in talks to buy Revolution in a deal that could have valued the cancer-drug developer at around $30 billion. However, the discussions cooled after the two ...
(RTTNews) - Merck & Co Inc. (MRK) is no longer in discussions to acquire biotech company Revolution Medicines, according to a report from the Wall Street Journal citing people familiar with the matter. The pharmaceutical giant had recently been in talks to buy Revolution in a deal that could have valued the cancer-drug developer at around $30 billion. However, the discussions cooled after the two sides failed to reach an agreement on price, the report noted. While the talks have ended for now, it remains possible that negotiations could restart or that another suitor could emerge. Revolution Medicines is expected to release closely watched clinical testing data for its pancreatic and colorectal cancer drug candidates during the first half of this year, which could influence future interest. Earlier this month, the Wall Street Journal reported that AbbVie was in advanced talks for a potential deal with Revolution, which had attracted multiple suitors. AbbVie later clarified that it "is not in discussions" with the company. RVMD closed at $117.68 on January 23, 2026, down $1.09 or 0.92% at the end of regular trading. In overnight trading at 9:18 PM EST, the stock dropped sharply to $95.00, a decline of $22.68 or 19.27%. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.